We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+13.84%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$372M
AUM Growth
+$4.91M
(+1.3%)
Cap. Flow
-$25.8M
Cap. Flow
% of AUM
-6.95%
Top 10 Holdings %
Top 10 Hldgs %
47.82%
Holding
98
New
8
Increased
10
Reduced
34
Closed
10
Top Buys
| 1 |
Revolution Medicines
RVMD
|
+$3.96M |
| 2 |
MediWound
MDWD
|
+$2.57M |
| 3 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$2.16M |
| 4 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
+$1.4M |
| 5 |
Kura Oncology
KURA
|
+$1.37M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$6.71M |
| 2 |
NTUS
Natus Medical Inc
NTUS
|
+$4.71M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$3.96M |
| 4 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$3.65M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$2.28M |
Sector Composition
| 1 | Healthcare | 81.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $44.9M | 12.07% |
566,000
-47,000
| -8% | -$3.96M |
|
2
Stereotaxis
STXS
$161M
| $24.6M | 6.62% |
13,680,554
| – | – |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $17.2M | 4.63% |
261,235
-45
| -0% | -$2.89K |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $16.6M | 4.48% |
110,100
| – | – |
|
5
Ascendis Pharma A/S
ASND
$17.6B
| $14M | 3.77% |
135,712
-3,500
| -3% | -$332K |
|
|
6
Xenon Pharmaceuticals
XENE
$6.55B
| $13.5M | 3.64% |
375,223
-63,400
| -14% | -$2.28M |
|
7
Adicet Bio
ACET
$81.1M
| $13.3M | 3.58% |
58,485
| – | – |
|
8
Fate Therapeutics
FATE
$349M
| $12.1M | 3.25% |
539,940
-11,000
| -2% | -$318K |
|
9
iShares Biotechnology ETF
IBB
$9.24B
| $12M | 3.22% |
102,500
| – | – |
|
|
10
Revolution Medicines
RVMD
$39.2B
| $9.46M | 2.54% |
479,785
+180,000
| +60% | +$3.96M |
|
11
Cytokinetics
CYTK
$11.2B
| $8.91M | 2.4% |
183,995
-27,500
| -13% | -$1.32M |
|
12
Syndax Pharmaceuticals
SNDX
$2.08B
| $8.54M | 2.3% |
355,487
-15,500
| -4% | -$348K |
|
13
Neurocrine Biosciences
NBIX
$17.3B
| $8.51M | 2.29% |
80,155
-2,500
| -3% | -$254K |
|
14
IDEAYA Biosciences
IDYA
$3.54B
| $8.04M | 2.16% |
538,561
-10,000
| -2% | -$130K |
|
15
Edgewise Therapeutics
EWTX
$4.39B
| $7.69M | 2.07% |
781,112
+85,153
| +12% | +$860K |
|
16
Nurix Therapeutics
NRIX
$2.48B
| $7.38M | 1.99% |
566,695
| – | – |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.2M | 1.94% |
401,476
-1,000
| -0.2% | -$13.1K |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $7.06M | 1.9% |
180,306
| – | – |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.5M | 1.75% |
28,886
-33,167
| -53% | -$6.71M |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| $5.96M | 1.6% |
1,703,235
-84,334
| -5% | -$303K |
|
21
DexCom
DXCM
$28.1B
| $5.84M | 1.57% |
72,552
| – | – |
|
|
MRUS
22
DELISTED
Merus
MRUS
| $5.55M | 1.49% |
276,893
+14,002
| +5% | +$334K |
|
|
MORF
23
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.53M | 1.49% |
195,467
| – | – |
|
24
Alector
ALEC
$167M
| $5.04M | 1.35% |
532,438
-20,000
| -4% | -$216K |
|
|
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5M | 1.35% |
71,600
-8,000
| -10% | -$592K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML